Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

Merck and Daiichi abandon accelerated approval plans for lung cancer ADC

Merck and Daiichi Sankyo ended plans to seek accelerated FDA approval for their antibody-drug conjugate I-DXd in lung cancer after the agency indicated existing data wouldn't support the pathway, erasing a competitive advantage over rivals.